<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Smith &amp; Nephew Plc — News on 6ix</title>
    <link>https://6ix.com/company/smith-and-nephew-plc</link>
    <description>Latest news and press releases for Smith &amp; Nephew Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 22 Apr 2026 07:46:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/smith-and-nephew-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d5885fbeedb30cb6f8c9b7.webp</url>
      <title>Smith &amp; Nephew Plc</title>
      <link>https://6ix.com/company/smith-and-nephew-plc</link>
    </image>
    <item>
      <title>Notice of Results</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/notice-of-results-461</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/notice-of-results-461</guid>
      <pubDate>Wed, 22 Apr 2026 07:46:00 GMT</pubDate>
      <description>Smith+Nephew will release its first quarter 2026 trading report on Wednesday, May 6, 2026, at 7:00 AM BST, followed by a conference call for financial analysts at 8:30 AM BST. The company, which generated $6.2 billion in sales in 2025, operates in over 100 countries across Orthopaedics, Sports Medicine &amp; ENT, and Advanced Wound Management. This announcement provides the timing for the release of financial performance data for the quarter ending March 28, 2026.
                Disclaimer*</description>
    </item>
    <item>
      <title>New data for Smith+Nephew’s CARTIHEAL◊ AGILI-...</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/new-data-for-smithnephews-cartiheal-agili</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/new-data-for-smithnephews-cartiheal-agili</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 GMT</pubDate>
      <description>Smith+Nephew announced compelling 5-year results for its CARTIHEAL AGILI-C Cartilage Repair Implant, demonstrating superior pain relief and functional gains compared to the surgical standard of care, with patients experiencing twice the reduction in pain scores. The implant showed comparable clinical outcomes for both osteoarthritis and non-osteoarthritis patients, offering a new option for those in the treatment gap between cartilage repair and joint replacement. The FDA-approved implant, compo</description>
    </item>
    <item>
      <title>Director/PDMR Shareholding</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/directorpdmr-shareholding-851</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/directorpdmr-shareholding-851</guid>
      <pubDate>Thu, 16 Apr 2026 10:12:00 GMT</pubDate>
      <description>Smith &amp; Nephew plc announced on April 16, 2026, that awards of ordinary shares were granted on April 15, 2026, under the company&apos;s RISE Share Plan. These awards, valued at nil cost, were made to persons discharging managerial responsibilities (PDMRs), including the Chief Executive Officer and Chief Financial Officer, with each receiving 50 ordinary shares of US$0.20 each. This notification is an initial disclosure under the UK Market Abuse Regulation.
                Disclaimer*</description>
    </item>
    <item>
      <title>Director Declaration</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/director-declaration-426</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/director-declaration-426</guid>
      <pubDate>Wed, 15 Apr 2026 14:46:00 GMT</pubDate>
      <description>Smith &amp; Nephew plc has announced that Thérèse Esperdy, Senior Independent Director designate, will join the Board of Rentokil Initial plc as a Non-Executive Director and Chair-designate effective July 1, 2026, and as Chair from September 1, 2026. This disclosure is made in accordance with UK Listing Rule 6.4.9R(2).
                Disclaimer*</description>
    </item>
    <item>
      <title>Replacement: Annual Financial Report &amp; AGM Notice</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/replacement-annual-financial-report-and-agm-notice</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/replacement-annual-financial-report-and-agm-notice</guid>
      <pubDate>Tue, 14 Apr 2026 13:59:00 GMT</pubDate>
      <description>Smith &amp; Nephew Plc has amended its Annual Financial Report &amp; Notice of AGM announcement, originally released on March 16, 2026, to clarify that hard copies of the 2025 Annual Report, Notice of the 2026 Annual General Meeting, Form of Proxy, and proposed new Articles of Association are available free of charge upon request. These documents have also been uploaded to the National Storage Mechanism and the company&apos;s website, with the 2025 Annual Report on Form 20-F filed with the SEC. All other det</description>
    </item>
    <item>
      <title>Smith+Nephew’s REGENETEN◊ Bioinductive Implan...</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/smithnephews-regeneten-bioinductive-implan</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/smithnephews-regeneten-bioinductive-implan</guid>
      <pubDate>Thu, 09 Apr 2026 11:30:00 GMT</pubDate>
      <description>Smith+Nephew announced compelling new randomized control trial data for its REGENETEN Bioinductive Implant, showing post-operative recovery times for partial-thickness rotator cuff tears were halved compared to traditional suture anchor repair, with driving recovery reduced from 5.1 to 2.3 weeks and office work from 3.6 to 1.7 weeks. The study, published in the Orthopaedic Journal of Sports Medicine, also indicated improved quality of life and high tendon healing rates at one year, comparable to</description>
    </item>
    <item>
      <title>Total Voting Rights</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/total-voting-rights-977</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/total-voting-rights-977</guid>
      <pubDate>Wed, 01 Apr 2026 11:23:00 GMT</pubDate>
      <description>Smith &amp; Nephew plc has announced that as of March 31, 2026, its total issued share capital consists of 877,733,750 ordinary shares, with 23,761,952 of these held in treasury. Consequently, the number of ordinary shares with voting rights is 853,971,798, which shareholders should use as the denominator for calculating notification requirements under the FCA&apos;s Disclosure Guidance and Transparency Rules.
                Disclaimer*</description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/holdings-in-company-1332</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/holdings-in-company-1332</guid>
      <pubDate>Tue, 24 Mar 2026 08:45:00 GMT</pubDate>
      <description>Cevian Capital II GP Limited, through its managed funds, has increased its stake in Smith &amp; Nephew Plc to 10.094356%, acquiring 85,790,848 voting rights. This represents a significant increase from their previous holding of 5.021046%. The acquisition was completed on March 19, 2026, and notified to the issuer on March 23, 2026. The shares are held indirectly via Aurora Nominees Limited, acting as nominee for UBS AG.
                Disclaimer*</description>
    </item>
    <item>
      <title>Annual Financial Report &amp; Notice of AGM</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/annual-financial-report-and-notice-of-agm-83</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/annual-financial-report-and-notice-of-agm-83</guid>
      <pubDate>Mon, 16 Mar 2026 15:08:00 GMT</pubDate>
      <description>Smith &amp; Nephew plc has published its 2025 Annual Report and the Notice of the 2026 Annual General Meeting, along with a Form of Proxy and proposed new Articles of Association. These documents are available on the National Storage Mechanism and the company&apos;s website, with the 2025 Annual Report on Form 20-F also filed with the SEC. The company has confirmed that all regulated information required by Disclosure Guidance and Transparency Rule 6.3.5 is contained within the published 2025 Annual Repo</description>
    </item>
    <item>
      <title>Smith+Nephew launches next-generation ALLEVYN...</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/smithnephew-launches-next-generation-allevyn</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/smithnephew-launches-next-generation-allevyn</guid>
      <pubDate>Tue, 10 Mar 2026 14:30:00 GMT</pubDate>
      <description>Smith+Nephew has launched ALLEVYN COMPLETE CARE, a next-generation foam dressing designed for advanced wound management and pressure injury prevention. This five-layer dressing utilizes proprietary technologies proven to lock in significantly more exudate than other foam dressings, keep over 99% of bacteria away from the wound bed, and absorb up to 93% of mechanical energy to reduce pressure injury risk by over 65%. The dressing is expected to minimize leakage, enable longer wear times, and pote</description>
    </item>
    <item>
      <title>Smith+Nephew to feature leading rotator cuff ...</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/smithnephew-to-feature-leading-rotator-cuff</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/smithnephew-to-feature-leading-rotator-cuff</guid>
      <pubDate>Mon, 02 Mar 2026 18:00:00 GMT</pubDate>
      <description>Smith+Nephew will showcase its advanced rotator cuff repair portfolio at the AAOS 2026 meeting, featuring the newly acquired Tendon Seam™ Repair System and the REGENETEN◊ Bioinductive Implant. This combined offering aims to address the significant structural failure rates, ranging from 20-40%, associated with traditional rotator cuff repair techniques, which are performed approximately 500,000 times annually in the US. The Tendon Seam system, which received 510(k) clearance in 2023, provides a n</description>
    </item>
    <item>
      <title>BLOCK LISTING SIX MONTHLY RETURN</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/block-listing-six-monthly-return-211</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/block-listing-six-monthly-return-211</guid>
      <pubDate>Mon, 02 Feb 2026 16:00:00 GMT</pubDate>
      <description>Smith &amp; Nephew plc has provided a six-monthly return for its employee share plans covering the period from August 1, 2025, to January 31, 2026. The Global Share Plan 2010 has a remaining balance of 3,756 unallotted securities. The Smith &amp; Nephew ShareSave Plan (2012) has 432,252 unallotted securities, and the International ShareSave Plan (2012) has 612,504 unallotted securities. The Global Share Plan 2020 saw 14,695 securities issued, leaving a balance of 388,563 unallotted securities. The Smith</description>
    </item>
    <item>
      <title>Smith+Nephew completes acquisition of Integri...</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/smithnephew-completes-acquisition-of-integri</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/smithnephew-completes-acquisition-of-integri</guid>
      <pubDate>Wed, 21 Jan 2026 17:15:00 GMT</pubDate>
      <description>Smith+Nephew has completed the acquisition of Integrity Orthopaedics, enhancing its sports medicine shoulder repair portfolio with the innovative Tendon Seam™ system designed to reduce re-tear rates and improve patient outcomes in rotator cuff repair procedures. This acquisition strengthens Smith+Nephew&apos;s offering in the US rotator cuff repair market, a segment with approximately 500,000 procedures annually where traditional methods face high structural failure rates of 20-40%. The Tendon Seam™ </description>
    </item>
    <item>
      <title>Acquisition of Integrity Orthopaedics</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/acquisition-of-integrity-orthopaedics</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/acquisition-of-integrity-orthopaedics</guid>
      <pubDate>Mon, 12 Jan 2026 16:30:00 GMT</pubDate>
      <description>Smith+Nephew has acquired Integrity Orthopaedics for an initial US$225 million cash payment plus up to US$225 million in performance-based payments over five years, aiming to strengthen its sports medicine portfolio with the Tendon Seam™ rotator cuff repair technology. This acquisition is expected to be accretive to Group trading profit margin by 2028 and is financed from existing cash facilities, keeping the Group below its leverage target of 2x EBITDA. The transaction, which is expected to clo</description>
    </item>
    <item>
      <title>New Strategy and 2028 Financial Targets</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/new-strategy-and-2028-financial-targets</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/new-strategy-and-2028-financial-targets</guid>
      <pubDate>Mon, 08 Dec 2025 07:00:00 GMT</pubDate>
      <description>Smith+Nephew has announced its new RISE strategy, aiming to drive shareholder value through enhanced financial and operational performance, with 2028 targets including a 6-7% revenue CAGR and 9-10% trading profit CAGR, and over $1 billion in free cash flow. The company has updated its 2025 full-year guidance, now expecting a trading profit margin of at least 19.5% and an upgraded free cash flow forecast of around $800 million, while also planning a $200 million non-cash inventory provision in 20</description>
    </item>
    <item>
      <title>Directorate change</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/directorate-change-1054</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/directorate-change-1054</guid>
      <pubDate>Thu, 06 Nov 2025 07:01:00 GMT</pubDate>
      <description>Directorate change.</description>
    </item>
    <item>
      <title>UFC® and Smith+Nephew announce multi-year ext...</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/ufcr-and-smithnephew-announce-multi-year-ext</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/ufcr-and-smithnephew-announce-multi-year-ext</guid>
      <pubDate>Wed, 22 Oct 2025 15:30:00 GMT</pubDate>
      <description>Smith+Nephew and UFC have extended their worldwide marketing partnership, initially established in 2024, for multiple years. Smith+Nephew will continue as UFC’s Preferred Sports Medicine Technology Partner. A highlight of the initial agreement was a medical education course, and a second course will be held in Las Vegas from February 18-20, 2026. UFC athletes will continue to be integrated into Smith+Nephew&apos;s marketing efforts, with Dustin &quot;The Diamond&quot; Poirier serving as a brand ambassador in 2</description>
    </item>
    <item>
      <title>Block listing Interim Review</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/block-listing-interim-review-341</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/block-listing-interim-review-341</guid>
      <pubDate>Thu, 16 Oct 2025 09:10:00 GMT</pubDate>
      <description>Smith &amp; Nephew Plc reports on their block listing six-monthly return from February 1, 2025, to July 31, 2025. Under the Global Share Plan 2010, 206 securities were issued/allotted, decreasing the balance of unallotted securities to 3,756. For the Global Share Plan 2020, 5,758 securities were issued/allotted, leaving a balance of 403,258 unallotted. No securities were issued or allotted during this period for the Smith &amp; Nephew ShareSave Plan (2012), Smith &amp; Nephew International ShareSave Plan (2</description>
    </item>
    <item>
      <title>Smith+Nephew announces new category I CPT® co...</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/smithnephew-announces-new-category-i-cptr-co</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/smithnephew-announces-new-category-i-cptr-co</guid>
      <pubDate>Thu, 09 Oct 2025 16:30:00 GMT</pubDate>
      <description>Smith+Nephew announced that the American Medical Association (AMA) CPT Editorial Panel has established a Category I Current Procedural Terminology (CPT) code for procedures involving its CARTIHEAL AGILI-C Cartilage Repair Implant, which will be effective January 1, 2027. Data from a multicenter randomized controlled trial demonstrated an 87% reduction in the relative risk of total knee arthroplasty or osteotomy at 4 years compared to microfracture or debridement with the CARTIHEAL Implant. The n</description>
    </item>
    <item>
      <title>Capital Markets Days</title>
      <link>https://6ix.com/company/smith-and-nephew-plc/news/capital-markets-days</link>
      <guid isPermaLink="true">https://6ix.com/company/smith-and-nephew-plc/news/capital-markets-days</guid>
      <pubDate>Wed, 08 Oct 2025 06:00:00 GMT</pubDate>
      <description>Smith+Nephew will host Capital Markets Days in London on December 8, 2025, and in New York on December 11, 2025, for institutional investors and financial analysts. The London event will focus on the company&apos;s new strategy following its 12-Point Plan, including mid-term priorities and financial goals, and will be held at The Royal College of Surgeons from 1pm to 5pm GMT. The New York event, taking place at the New York Stock Exchange from 2pm to 6pm GMT, will detail Smith+Nephew&apos;s innovative por</description>
    </item>
  </channel>
</rss>